What can we help you find?

Leading the way in transplantation

Filter results for:

OUR VISION

Infectious diseases (ID) have always been a significant threat in the management of solid organ transplant (SOT) recipients, often counterbalancing our efforts to control alloimmune response to prevent organ rejection. However, in recent years, the COVID-19 pandemic, the outbreak of new multi-drug resistant pathogens, and the availability of new antimicrobial agents enhanced the need for close interaction between the community of transplant physicians, surgeons, and infectious disease specialists. In the context of ESOT’s efforts to foster greater multidisciplinarity, we identified the need to convene a group of experts to work towards a strategy for assessing unmet needs and gaps related to ID in SOT. Therefore, the ESOT Council deliberated to establish a transversal task force of transplant professionals and infectious disease specialists to deliver activities in transplant infections.

The scope of this task force will be to assist ESOT and its Sections and Committees in planning and conducting activities focused on preventing and treating infectious complications in organ transplant recipients. The portfolio of this task force will include, but will not be limited to, ongoing projects in the transplant ID setting. These comprise the update of, and the dissemination activities related to, the COVID-19 position statement, the educational and scientific projects related to new CMV treatments coming to the market, the identification of needs for specific guidelines or position documents about clinical controversies in transplant ID management, and the related collaboration with industry in this setting.

Aims and objectives

Assist ESOT and its sections and committees in planning and conducting activities focused on the prevention and treatment of infectious complications in organ transplant recipients.

Current activities in the ID field and portfolio of the task force :

  • Update of and dissemination activities related to the COVID-19 position statement
  • Educational and scientific projects related to the new CMV treatments upcoming into the market
  • Identification of needs for specific guidelines or position documents about clinical controversies in transplant ID management
  • Collaboration with industry in this setting

Task Force

Jose Maria Aguado (Spain), Gregor Bond (Austria), Saskia Bos (United Kingdom), David Cucchiari (Spain), Paolo Grossi (Italy), Nassim Kamar (France), Hannah Kaminski (France), Oriol Manuel (Switzerland), Berta Saez-Gimenez (Spain), Ines Ushiro-Lumb (United Kingdom), Sophie Alain (France).

and with Liaisons

Anna Forsberg (Sweden), Luciano Potena (Italy), Luca Toti (Italy)

Join our community today!

Learn more